🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to evaluate the effectiveness of niraparib in ...
Status
Active Not Recruiting
Location
Urology Centers Of Alabama
Start Date
2019-01-25
Trial ID
NCT03748641
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance...
Status
Active Not Recruiting
Location
GSK Investigational Site
Start Date
2016-07-11
Trial ID
NCT02655016
Ovarian cancer is a heterogeneous disease, characterized by complex molecul...
Status
Active Not Recruiting
Location
GSK Investigational Site
Start Date
2018-10-11
Trial ID
NCT03602859
Treatments Being Tested
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlle...
Status
Completed
Location
GSK Investigational Site
Start Date
2013-06-21
Trial ID
NCT01847274
Treatments Being Tested
The purpose of the study is to determine if the combination of niraparib wi...
Status
Active Not Recruiting
Location
Urology Centers Of Alabama
Start Date
2020-09-23
Trial ID
NCT04497844
Study Title: A Multicenter, Randomized Controlled Trial of Tiaoshen Anti-ca...
Status
Not Yet Recruiting
Location
Shanghai Hospital of Traditional Chinese Medicine
Start Date
2026-05-01
Trial ID
NCT07550205
This is a 2 part study. Part 1 is to evaluate the efficacy and safety of do...
Status
Active Not Recruiting
Location
GSK Investigational Site
Start Date
2019-07-18
Trial ID
NCT03981796
This is a multicenter, randomized, double-blind, placebo-controlled study o...
Status
Completed
Location
GSK Investigational Site
Start Date
2020-10-26
Trial ID
NCT04475939
Treatments Being Tested
Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, plac...
Status
Unknown
Location
Anhui Provincal Hospital
Start Date
2018-06-30
Trial ID
NCT03709316
Treatments Being Tested
This is a 2:1 randomized, double-blind, placebo-controlled, multi-center, p...
Status
Unknown
Location
Cancer center of Guangzhou medical university
Start Date
2017-06-08
Trial ID
NCT03705156
Treatments Being Tested